John McMurray The VALIANT trial compared ACE-inhibitor, ARB and a combination of the two in high-risk post-MI patients, and found there may be an interaction between them and statins. John McMurray fr
John McMurray
The VALIANT trial compared ACE-inhibitor, ARB and a combination of the two in high-risk post-MI patients, and found there may be an interaction between them and statins.John McMurrayfrom the Western Infirmary in Glasgow.
Related Episodes
Audio Journal of Oncology Volume 16 Number 9
Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Commenting Expert: Emiel Rutgers, Netherlands Cancer Institute, Amsterdam Angel Rod
New Targets Bring Promise For Lung Cancer Therapy
Egbert Smit EGBERT SMIT, Free University of Amsterdam There are a number of promising new molecular targets for lung cancer chemotherapy which were discussed at the Turin congress by Egbert Smit. He t
Target Angiogenesis for Lung Cancer With Multiple Tyrosine Kinase Inhibitors
Silvia Novello SILVIA NOVELLO, University of Turin Future improvements in drug treatment of lung cancer may be made by inhibiting more than one tyrosine kinase simultaneously. So said Silvia Novello w